Table 1 Clinical demographics.

From: Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer’s disease in a large clinical sample

Diagnosis

N

Age

Gender

Aβ42/40 ratio

pTau(181)

tTau

Mean (SD)

Range

Females N (%)

Mean (SD)

Mean (SD)

Mean (SD)

CU

68

64.2 (7.53)

55–85

38 (55.9)

0.112 (0.015)

29.16 (10.61)

212.4 (74.2)

MCI-AD

95

70.7 (7.33)

56–86

44 (46.3)

0.052 (0.016) *,†,$

89.10 (46.55) *,†,#,$

442.6 (202.5)*,†,#,$

DEM-AD

72

71.5 (9.26)

56–93

33 (45.8)

0.053 (0.015)*,†,$

98.76 (50.91) *,†,#,$

470.3 (255.1)*,†,#,$

MCI-other

77

68.2 (7.59)

55–84

27 (35.1)

0.131 (0.197)

28.03 (18.48)

220.0 (115.1)

DEM-other

23

70.5 (9.51)

57–89

9 (39.1)

0.112 (0.023)

30.94 (21.10)

198.8 (89.8)

NPH

57

75.0 (7.73)

57–94

20 (35.1)

0.102 (0.027)

29.00 (21.66)

204.6 (114.1)

  1. CU = Cognitively unimpaired and includes 20 with no other specified neurological disorders, 18 patients evaluated for immune disease, 9 patients with other non-dementing neurodegenerative diseases, 6 patients with vascular disease, 5 with demyelinating disease, 4 patients with headache, 3 patients with psychiatric disease, 3 patients with idiopathic intracranial hypertension, and 1 patient with neoplasm, MCI-AD = mild cognitive impairment due to Alzheimer’s disease; DEM-AD = dementia due to Alzheimer’s disease, MCI-other = mild cognitive impairment due to other non-AD causes, DEM-other = dementia due to other non-AD causes, NPH = normal pressure hydrocephalus. Only MCI-AD and DEM-AD subjects had CSF AD biomarkers with low Aβ42/40 indicating AD. All others had normal Aβ42/40 above diagnostic threshold value. Group differences were assessed with ANOVA and p-values indicate results from post-hoc Tukey test.
  2. * = significantly different compared to CU (p < 0.05).
  3. † = significantly different compared to MCI-other (p < 0.05).
  4. # = significantly different compared to DEM-other (p < 0.05).
  5. $ = significantly different compared to NPH (p < 0.05).